[Estimation of level of soluble form PECAM-1, ICAM-2 and TNF-alpha, IL-18 in serum patients with chronic myelogenic leukemia].
The aim of this study was to estimate sPECAM-1, sICAM-2 and TNF-alpha and IL-18 concentrations in serum patients with chronic myelogenic leukemia. The results indicate of increased level sPECAM-1, sICAM-2 and TNF-alpha, IL-18 concentrations in serum patients with chronic myelogenic leukemia. Elevation levels of sPECAM-1 and sICAM-2 may lead to inhibit of making myelogenic leukemia cells infiltrations through the block of surface their receptors in patients with CML. High concentration of TNF-alpha and 11-18 in blood serum may indicate high expression of sPECAM-1 by activated specific enzymes responsible for releasing sPECAM-1.
Kiersnowska-Rogowska
Beata
B
Klinika Hematologil Akademii Medycznej w Białymstoku.
Izycka
Aneta
A
Jabłońska
Ewa
E
Rogowski
Franciszek
F
Parfieńczyk
Adam
A
D000293:Adolescent; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000097:blood*; D015815:Cell Adhesion Molecules / Q000097:blood*; D005260:Female; D006801:Humans; D020382:Interleukin-18 / Q000097:blood*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000097:blood*; D008297:Male; D008875:Middle Aged; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000097:blood*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D015703:Antigens, CD; D015815:Cell Adhesion Molecules; C065289:ICAM2 protein, human; D020382:Interleukin-18; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D014409:Tumor Necrosis Factor-alpha